| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
| ln Vivo |
Prednisone acetate (5 mg/kg, gavage, once daily, for 4 weeks) leads to neuronal damage in the hippocampus's dentate gyrus, which lowers glutamate (Glu) and NMDAR2A. This degrades the hippocampal LTP injury model mice. memory [1]. In patients with experimental autoimmune uveitis (EAU), prednisone acetate (6 mg/kg, gavage, once day for 15 days) improves peripheral regulatory responses in the eyes by regulating Notch signaling gain.
|
|---|---|
| Animal Protocol |
Animal/Disease Models: C57BL/6 mice[1]
Doses: 5 mg/kg Route of Administration: gavage (ig) Experimental Results:Body weight obviously failed to increase. Population peak value (%) diminished after high-frequency stimulation. The number of crossovers was diminished compared to the control group. It leads to memory impairment and creates a tendency for more severe impairment. Reduces glutamate and gamma-aminobutyric acid (GABA) levels in the hippocampus. diminished hippocampal N-methyl-D-aspartate receptor expression. Animal/Disease Models: Experimental autoimmune uveitis [2] Doses: 6 mg/kg Route of Administration: gavage Experimental Results: Symptoms in the eyes were diminished from the 9th day after immunization. diminished inflammation in EAU rats. Binds to pockets of Notch signaling-related molecules with good affinity. Exhibits anti-inflammatory effects by inhibiting Notch signaling activation. The frequencies of Th1 and Th17 diminished and the frequencies of Th2 and Treg increased in EAU. |
| References |
|
| Additional Infomation |
Cortancyl is a steroid ester, a 20-oxo steroid, an acetate ester, a 17alpha-hydroxy steroid, an 11-oxo steroid, a 3-oxo-Delta(1),Delta(4)-steroid and a tertiary alpha-hydroxy ketone. It is functionally related to a prednisone.
|
| Molecular Formula |
C23H28O6
|
|---|---|
| Molecular Weight |
400.47
|
| Exact Mass |
400.188
|
| CAS # |
125-10-0
|
| Related CAS # |
Prednisone;53-03-2;Prednisone acetate-d3
|
| PubChem CID |
91438
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
582.0±50.0 °C at 760 mmHg
|
| Melting Point |
240-242°C (dec.)
|
| Flash Point |
200.2±23.6 °C
|
| Vapour Pressure |
0.0±3.7 mmHg at 25°C
|
| Index of Refraction |
1.580
|
| LogP |
2.66
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
29
|
| Complexity |
869
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(CC(=O)[C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)C)O
|
| InChi Key |
MOVRKLZUVNCBIP-RFZYENFJSA-N
|
| InChi Code |
InChI=1S/C23H28O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h6,8,10,16-17,20,28H,4-5,7,9,11-12H2,1-3H3/t16-,17-,20+,21-,22-,23-/m0/s1
|
| Chemical Name |
[2-[(8S,9S,10R,13S,14S,17R)-17-hydroxy-10,13-dimethyl-3,11-dioxo-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~62.43 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.24 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.19 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.19 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4971 mL | 12.4853 mL | 24.9707 mL | |
| 5 mM | 0.4994 mL | 2.4971 mL | 4.9941 mL | |
| 10 mM | 0.2497 mL | 1.2485 mL | 2.4971 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Androgen Deprivation Therapy Combined With Docetaxel for High Risk Prostate Cancer
CTID: NCT04869371
Phase: Phase 2 Status: Unknown status
Date: 2022-12-29
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
